


Figure S2 Bayesian ranking profiles of comparable treatments on efficacy for patients with non-small cell lung cancer.

Profiles indicate the probability of each comparable treatment being ranked from first to last on progression free survival (PFS) and overall survival (OS). SoC: standard of care, represents first generation EGFR-TKIs in this network meta-analysis (including gefitinib, erlotinib and icotinib).

a. Afatinib; b. Chemotherapy; c. Dacomitinib; d. Osimertinib; e. SoC; f. SoC+Apatinib; g. SoC+Bevacizumab; h. SoC+Chemotherapy; i. SoC+Mono-chemotherapy; j. SoC+Ramucirumab


a

Afatinib




b


Chemotherapy




C

Dacomitinib




d**Osimertinib**

SoC




f

SoC+Apatinib




9

SoC+Bevacizumab




h

SoC+Chemotherapy



SoC+Mono-chemotherapy



SoC+Ramucirumab

